Direct evidence is thin. The claim is plausible and aligns with adjacent findings, but there isn't yet a body of high-quality work that would let us call it well-supported on its own terms.
how much of that benefit is through a toff adji i'd like to turn that question to you how much of it is through inhibition of senescence cells reduction of inflammation again so it's very indirect and it speaks to again again I don't mean to sound like a conspiracy theory guy because I'm not but it is a little frustrating that we have these amazing tools but because they're not particularly profitable you don't really have somebody that's interested in answering them
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
I think it's true that we still don't fully understand the mechanisms by which mtor inhibition and rapy can impact the biology of aging and therefore we're working with incomplete models.
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.